Atomo Diagnostics (ASX:AT1) ROCE % : -62.03% (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Atomo Diagnostics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Atomo Diagnostics's annualized ROCE % for the quarter that ended in Dec. 2024 was -62.03%.

Atomo Diagnostics ROCE % Historical Data

The historical data trend for Atomo Diagnostics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atomo Diagnostics ROCE % Chart

Atomo Diagnostics Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Jun24

ROCE %

-11.37

-18.59

-20.62

-55.94

-56.90

Atomo Diagnostics Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROCE %	Get a 7-Day Free Trial						-56.52	-57.30	-51.81	-57.13	-62.03

Atomo Diagnostics ROCE % Calculation

Atomo Diagnostics's annualized ROCE % for the fiscal year that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	-7.161	/	( ( (16.474 - 1.495)	+	(11.379 - 1.188) )	/ 2 )
	=	-7.161	/	( (14.979	+	10.191)	/ 2 )
	=	-7.161	/	12.585
	=	-56.90 %

Atomo Diagnostics's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Jun. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Jun. 2024 )		(Q: Dec. 2024 )
	=	-5.504	/	( ( (11.379 - 1.188)	+	(9.249 - 1.694) )	/ 2 )
	=	-5.504	/	( ( 10.191	+	7.555 )	/ 2 )
	=	-5.504	/	8.873
	=	-62.03 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

Atomo Diagnostics (ASX:AT1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Atomo Diagnostics ROCE % Related Terms

Thank you for viewing the detailed overview of Atomo Diagnostics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Atomo Diagnostics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Atomo Diagnostics Ltd (ASX:AT1) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 - 5 George Street, Level 1, Leichhardt, Syndey, NSW, AUS, 2040

Website

https://www.atomodiagnostics.com

Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company is engaged in the development and sale of medical devices. The company develops point-of-care devices for rapid diagnostic testing. The company offers AtomoRapid RDT Platform with devices including Galileo, Pascal, Curie, and Elion. The firm operates in a single segment, medical device research and development.

Atomo Diagnostics Headlines

No Headlines